MT 103 - CURACLE
Alternative Names: MT-103- CURACLELatest Information Update: 22 Jan 2024
At a glance
- Originator CURACLE
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Retinal disorders